SCHEMBL20447809

SCHEMBL20447809

Cc1ccc(CNC(=O)OC(C)(C)C)c(Br)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HDAC10 Q969S8 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
NAMPT P43490 2/20 0.40
BCHE P06276 1/20 0.40
FPR3 P25089 1/20 0.40
FPR2 P25090 1/20 0.40
CACNA1H O95180 1/20 0.40
CACNA1B Q00975 1/20 0.40
CACNA1C Q13936 1/20 0.40
KCNA5 P22460 1/20 0.40
BRD4 O60885 1/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
MAPKAPK2 P49137 1/20 0.38
GAA P10253 2/20 0.38
NQO2 P16083 1/20 0.38
GRM2 Q14416 1/20 0.38
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29578574 1.00 KDM4A (0.43) KDM4AL3MBTL1HDAC10HDAC6NAMPT
SCHEMBL29664294 0.82 KDM4A (0.44) KDM4AL3MBTL1NAMPTBCHEKDM4E
SCHEMBL16814047 0.82 KDM4A (0.44) KDM4AL3MBTL1HDAC10HDAC6NAMPT
SCHEMBL20447884 0.81 ALDH1A1 (0.36) HDAC6KDM4EMEN1NPC1RAB9A
SCHEMBL17018589 0.78 NAMPT (0.46) KDM4AL3MBTL1HDAC10HDAC6NAMPT
SCHEMBL35210561 0.78 NAMPT (0.46) KDM4AL3MBTL1HDAC10HDAC6NAMPT
SCHEMBL16793700 0.76 AAK1 (0.49) KDM4AHDAC10HDAC6FPR3FPR2
SCHEMBL31432005 0.75 F2 (0.47) KDM4AMAPKAPK2
SCHEMBL1900426 0.75 F2 (0.47) KDM4AMAPKAPK2
SCHEMBL31437524 0.75 MAPKAPK2 (0.43) KDM4AL3MBTL1NAMPTBCHECACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3356344-B1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY ASTEX THERAPEUTICS LTD (GB) 2022-11-16 EP disclosed
CN-108473464-B Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity 阿斯泰克斯治疗有限公司 2022-08-23 CN disclosed
US-20220106287-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY ASTEX THERAPEUTICS LIMITED (GB) 2022-04-07 US disclosed
US-11261171-B1 Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity ASTEX THERAPEUTICS LIMITED (GB) 2022-03-01 US disclosed
US-20190055215-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY ASTEX THERAPEUTICS LIMITED (GB) 2019-02-21 US disclosed
EP-3356344-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY Astex Therapeutics Ltd (GB) 2018-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220106287-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY TP53, MDM2, TP53BP1 KDM4A 3292/4885L3MBTL1 3091/4885HDAC10 1781/4885
US-20190055215-A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY TP53, MDM2, TP53BP1 KDM4A 3292/4885L3MBTL1 3091/4885HDAC10 1781/4885
US-11261171-B1 Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity TP53, MDM2, TP53BP1 KDM4A 3292/4885L3MBTL1 3091/4885HDAC10 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.